查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
罕見病診斷市場 - 2017-2027年全球行業規模、佔有率、趨勢、機會和預測，按適應症、按性狀類型、按測試類型、按技術、按樣本類型、按終端用戶、按公司和按地區分類
市場調查報告書
商品編碼
1289657

罕見病診斷市場 - 2017-2027年全球行業規模、佔有率、趨勢、機會和預測，按適應症、按性狀類型、按測試類型、按技術、按樣本類型、按終端用戶、按公司和按地區分類

Rare Disease Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Indication, By Trait Type, By Test Type, By Technology, By Sample Type, By End User, By company and By Region
出版日期: | 出版商: TechSci Research | 英文 117 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

在2023-2027年的預測期內，全球罕見病診斷市場預計將出現令人矚目的成長。主要因素包括罕見疾病發病率的成長、先進技術的採用以及研發投資的增加都在推動著市場的成長。罕見病或孤兒病是指影響一小部分人口的任何疾病。支持市場成長的其他因素是，政府不斷增加宣傳計劃，擴大罕見疾病患者登記冊，測序成本下降，老年人口增加，罕見疾病診斷項目和新產品開發不斷推出，以及研發活動的增加。

罕見疾病發病率的上升將推動市場的成長。

罕見病並不罕見，因為有很多人正在遭受這種疾病。它們比艾滋病和癌症的組合影響更多的人。例如，根據《歐洲人類遺傳學雜誌》，全球患有罕見疾病的人數估計為3億人。由於患有罕見疾病的人數增加，如丙種球蛋白血症、古德帕斯特症候群、多發性肉芽腫病（GPA，原韋格納肉芽腫病）、白細胞粘附缺陷症、小兒布魯頓丙種球蛋白血症、小兒嚴重聯合免疫缺陷症、施尼茨勒症候群等，對診斷的需求激增，促進了市場的成長。

疾病診斷方面的技術進步

罕見病診斷領域採用先進技術的增加正在增強市場的成長。新的創新技術和進步，如人工智慧（AI）、基於NGS的測試和自動化技術，有助於減少時間和成本，與標準的人工分析相比，能夠實現更準確的診斷。例如，增加採用全外顯子組測序（WES）的基因測試工具。該技術只針對外顯子，它佔整個基因組的1-2%，包括所有致病突變的80%。

對診斷罕見病的認知不斷提高

罕見病的早期診斷是至關重要的，因為它可以幫助人們及時治療這些疾病而不至於遭受痛苦。因此，公眾和患者對罕見病認知的提高，促進了市場的成長。政府和非政府組織採取了各種計劃，讓人們了解疾病的早期診斷和治療。例如，美國國立衛生研究院每年都會舉辦罕見病日，旨在提高人們對罕見病的認知以及它們對患者生活的影響。

可用的定製服務

利用給定的市場數據，TechSci Research根據公司的具體需求提供定製服務。該報告有以下定製選項：

公司資訊

  • 其他市場參與者（最多5家）的詳細分析和概況。

目錄

第一章：產品概述

第二章：研究方法

第三章：執行摘要

第四章：COVID-19對全球罕見病診斷市場的影響

第五章：客戶的聲音

第六章：全球罕見病診斷市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按適應症（消化系統疾病、內分泌和代謝疾病、心血管疾病、血液和腫瘤疾病、其他）分類
    • 按性狀類型（遺傳性與獲得性）分類
    • 按測試類型（基因測試、普通實驗室測試、影像診斷、其他）
    • 按技術分類（下一代測序、全基因組測序、全外顯子組測序、晶片、其他）
    • 按樣本類型（DNA樣本、血液樣本、唾液樣本、其他）
    • 按終端用戶（醫院和診所、學術和研究機構、其他）分類
    • 按地區分類
    • 按公司分類（2021年）
  • 市場地圖

第七章：北美罕見病診斷市場展望

  • 市場規模和預測
    • 按價值分類
  • 市場佔有率與預測
    • 按適應症分類
    • 按性狀類型
    • 按測試類型
    • 按技術分類
    • 按樣品類型
    • 按終端用戶分類
    • 按國家分類
  • 北美洲：國家分析
    • 美國
    • 美國
    • 墨西哥

第8章：歐洲罕見病診斷市場前景

  • 市場規模和預測
    • 按價值
  • 市場佔有率與預測
    • 按適應症分類
    • 按性狀類型
    • 按測試類型
    • 按技術分類
    • 按樣品類型
    • 按終端用戶分類
    • 按國家分類
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第九章：亞太地區罕見病診斷市場前景

  • 市場規模和預測
    • 按價值
  • 市場佔有率與預測
    • 按適應症分類
    • 按性狀類型
    • 按測試類型
    • 按技術分類
    • 按樣品類型
    • 按終端用戶分類
    • 按國家分類
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞

第十章：南美罕見病診斷市場前景

  • 市場規模和預測
    • 按價值
  • 市場佔有率與預測
    • 按適應症分類
    • 按性狀類型
    • 按測試類型
    • 按技術分類
    • 按樣品類型
    • 按終端用戶分類
    • 按國家分類
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第11章：中東和非洲的罕見病診斷市場前景

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按適應症分類
    • 按性狀類型
    • 按測試類型
    • 按技術分類
    • 按樣品類型
    • 按終端用戶分類
    • 按國家分類
  • MEA: 國家分析
    • 南非罕見病診斷法
    • 沙烏地阿拉伯罕見病診斷
    • 阿拉伯聯合大公國罕見病診斷

第十二章：市場動態

  • 驅動力
  • 挑戰

第十三章：市場趨勢和發展

第十四章：競爭格局（包括SWOT分析）

  • 安捷倫科技公司（Agilent Technologies, Inc.
  • Illumina, Inc.
  • QIAGEN NV
  • 珀金埃爾默公司
  • Quest Diagnostics, Inc.
  • CENTOGENE NV
  • 23andMe, Inc.
  • 3billion, Inc.
  • Eurofins Scientific SE
  • Invitae公司

第十五章：戰略建議

簡介目錄
Product Code: 13047

The global rare disease diagnostics market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors include the growing incidence of rare disorders, adoption of advanced technology, and increase in investments in R&D are impelling the growth of the market. Rare diseases or orphan diseases is any disease that affects a small percentage of the population. The other factors supporting the market's growth are, increasing government initiatives for spreading awareness, expanding patient registry for rare diseases, declining sequencing cost, rising geriatric population, the growing launch of programs & new product development in rare disease diagnosis, and rise in research and development activities.

The rising incidence of rare disorders will fuel the market growth.

Rare diseases are not rarer as there are many people who are suffering from the disease. They affect more people than the combination of AIDS & Cancer. For instance, as per the European Journal of Human Genetics, the number of people living with a rare disease is estimated at 300 million across the globe. Owing to the rise in the number of people suffering from rare diseases such as Agammaglobulinemia, Goodpasture Syndrome, Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis), Leukocyte Adhesion Deficiency, Pediatric Bruton Agammaglobulinemia, Pediatric Severe Combined Immunodeficiency, Schnitzler Syndrome and others, the surge in demand for the diagnosis is bolstering the growth of the market.

Technological Advancements in Disease Diagnosis

The rise in the adoption of advanced technology in the field of rare diseases diagnostic is augmenting the growth of the market. New innovative technologies and advancements such as artificial intelligence (AI), NGS-based testing, and automation technology are assisting in reducing time and cost and enabling more accurate diagnosis when compared to standard manual analysis. For instance, increase in the adoption of the Whole Exome Sequencing (WES) genetic testing tool. The technique aims only at exons, which make 1-2% of the whole genome and include 80% of all disease-causing mutations.

Rising Awareness of diagnosis of rare diseases

Early diagnosis of rare diseases is essential as it can help people to treat these conditions timely without suffering. Thus, the rise in awareness about rare diseases among the general public and patients is facilitating the growth of the market. Various initiatives by government and non-government organizations are taken to make people aware of the early diagnosis and treatment of the disease. For instance, every year, rare diseases day at NIH takes place, which aims to raise awareness about rare diseases and the impact they have on patient's lives.

Market Segmentation

The global rare disease diagnostics market is segmented into indication, trait type, test type, technology, sample type, end user, and company. Based on indication, the market is divided into gastroenterology disease, endocrine & metabolism disorders disease, cardiovascular disorders, hematology & oncology disease, and others. Based on trait type, the market is divided into inherited and acquired. Based on test type, the market is segmented into genetic tests, general lab tests, diagnostic imaging, and others. Based on technology, the market is divided into next-generation sequencing, whole genome sequencing, whole exome sequencing, microarrays, and others. Based on sample type, the market is divided into DNA samples, blood sample, saliva samples, and others. Based on end-user, the market is divided into hospitals & clinics, academic & research institutes, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising occurrences of rare diseases in the country.

Market Players

Agilent Technologies, Inc., Illumina, Inc., QIAGEN NV, PerkinElmer, Inc, Quest Diagnostics, Inc., CENTOGENE N.V., 23andMe, Inc., 3billion, Inc., Eurofins Scientific SE, and Invitae Corporation are some of the leading companies operating in the market.

Report Scope

In this report, global rare disease diagnostics market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Rare Disease Diagnostics Market, By Indication:

  • Gastroenterology Disease
  • Endocrine & Metabolism Disorders Disease
  • Cardiovascular Disorders
  • Hematology & Oncology Disease
  • Others

Rare Disease Diagnostics Market, By Trait Type:

  • Inherited
  • Acquired

Rare Disease Diagnostics Market, By Test Type:

  • Genetic Tests
  • General Lab Tests
  • Diagnostic Imaging
  • Others

Rare Disease Diagnostics Market, By Technology:

  • Next Generation Sequencing
  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • Microarrays
  • Others

Rare Disease Diagnostics Market, By Sample Type:

  • DNA Sample
  • Blood Sample
  • Saliva Sample
  • Others

Rare Disease Diagnostics Market, By End User:

  • Hospitals & Clinics
  • Academic & Research Institutes
  • Others

Rare Disease Diagnostics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Rare Disease Diagnostics Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Rare Disease Diagnostics Market

5. Voice of Customer

6. Global Rare Disease Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication (Gastroenterology Disease, Endocrine & Metabolism Disorders Disease, Cardiovascular Disorders, Hematology & Oncology Disease, Others)
    • 6.2.2. By Trait Type (Inherited v/s Acquired)
    • 6.2.3. By Test Type (Genetic Tests, General Lab Tests, Diagnostic Imaging, Others)
    • 6.2.4. By Technology (Next Generation Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Microarrays, Others)
    • 6.2.5. By Sample Type (DNA Sample, Blood Sample, Saliva Sample, Others)
    • 6.2.6. By End User (Hospitals & Clinics, Academic & Research Institutes, Others)
    • 6.2.7. By Region
    • 6.2.8. By Company (2021)
  • 6.3. Market Map

7. North America Rare Disease Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Trait Type
    • 7.2.3. By Test Type
    • 7.2.4. By Technology
    • 7.2.5. By Sample Type
    • 7.2.6. By End User
    • 7.2.7. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Rare Disease Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Trait Type
        • 7.3.1.2.3. By Test Type
        • 7.3.1.2.4. By Technology
        • 7.3.1.2.5. By Sample Type
        • 7.3.1.2.6. By End User
    • 7.3.2. Canada Rare Disease Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Trait Type
        • 7.3.2.2.3. By Test Type
        • 7.3.2.2.4. By Technology
        • 7.3.2.2.5. By Sample Type
        • 7.3.2.2.6. By End User
    • 7.3.3. Mexico Rare Disease Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Trait Type
        • 7.3.3.2.3. By Test Type
        • 7.3.3.2.4. By Technology
        • 7.3.3.2.5. By Sample Type
        • 7.3.3.2.6. By End User

8. Europe Rare Disease Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Trait Type
    • 8.2.3. By Test Type
    • 8.2.4. By Technology
    • 8.2.5. By Sample Type
    • 8.2.6. By End User
    • 8.2.7. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Rare Disease Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Trait Type
        • 8.3.1.2.3. By Test Type
        • 8.3.1.2.4. By Technology
        • 8.3.1.2.5. By Sample Type
        • 8.3.1.2.6. By End User
    • 8.3.2. Germany Rare Disease Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Trait Type
        • 8.3.2.2.3. By Test Type
        • 8.3.2.2.4. By Technology
        • 8.3.2.2.5. By Sample Type
        • 8.3.2.2.6. By End User
    • 8.3.3. United Kingdom Rare Disease Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Trait Type
        • 8.3.3.2.3. By Test Type
        • 8.3.3.2.4. By Technology
        • 8.3.3.2.5. By Sample Type
        • 8.3.3.2.6. By End User
    • 8.3.4. Italy Rare Disease Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Trait Type
        • 8.3.4.2.3. By Test Type
        • 8.3.4.2.4. By Technology
        • 8.3.4.2.5. By Sample Type
        • 8.3.4.2.6. By End User
    • 8.3.5. Spain Rare Disease Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Trait Type
        • 8.3.5.2.3. By Test Type
        • 8.3.5.2.4. By Technology
        • 8.3.5.2.5. By Sample Type
        • 8.3.5.2.6. By End User

9. Asia-Pacific Rare Disease Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Trait Type
    • 9.2.3. By Test Type
    • 9.2.4. By Technology
    • 9.2.5. By Sample Type
    • 9.2.6. By End User
    • 9.2.7. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Rare Disease Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Trait Type
        • 9.3.1.2.3. By Test Type
        • 9.3.1.2.4. By Technology
        • 9.3.1.2.5. By Sample Type
        • 9.3.1.2.6. By End User
    • 9.3.2. India Rare Disease Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Trait Type
        • 9.3.2.2.3. By Test Type
        • 9.3.2.2.4. By Technology
        • 9.3.2.2.5. By Sample Type
        • 9.3.2.2.6. By End User
    • 9.3.3. Japan Rare Disease Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Trait Type
        • 9.3.3.2.3. By Test Type
        • 9.3.3.2.4. By Technology
        • 9.3.3.2.5. By Sample Type
        • 9.3.3.2.6. By End User
    • 9.3.4. South Korea Rare Disease Diagnostics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Indication
        • 9.3.4.2.2. By Trait Type
        • 9.3.4.2.3. By Test Type
        • 9.3.4.2.4. By Technology
        • 9.3.4.2.5. By Sample Type
        • 9.3.4.2.6. By End User
    • 9.3.5. Australia Rare Disease Diagnostics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Indication
        • 9.3.5.2.2. By Trait Type
        • 9.3.5.2.3. By Test Type
        • 9.3.5.2.4. By Technology
        • 9.3.5.2.5. By Sample Type
        • 9.3.5.2.6. By End User

10. South America Rare Disease Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Trait Type
    • 10.2.3. By Test Type
    • 10.2.4. By Technology
    • 10.2.5. By Sample Type
    • 10.2.6. By End User
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Rare Disease Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Trait Type
        • 10.3.1.2.3. By Test Type
        • 10.3.1.2.4. By Technology
        • 10.3.1.2.5. By Sample Type
        • 10.3.1.2.6. By End User
    • 10.3.2. Argentina Rare Disease Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Trait Type
        • 10.3.2.2.3. By Test Type
        • 10.3.2.2.4. By Technology
        • 10.3.2.2.5. By Sample Type
        • 10.3.2.2.6. By End User
    • 10.3.3. Colombia Rare Disease Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Trait Type
        • 10.3.3.2.3. By Test Type
        • 10.3.3.2.4. By Technology
        • 10.3.3.2.5. By Sample Type
        • 10.3.3.2.6. By End User

11. Middle East and Africa Rare Disease Diagnostics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Indication
    • 11.2.2. By Trait Type
    • 11.2.3. By Test Type
    • 11.2.4. By Technology
    • 11.2.5. By Sample Type
    • 11.2.6. By End User
    • 11.2.7. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Rare Disease Diagnostics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Indication
        • 11.3.1.2.2. By Trait Type
        • 11.3.1.2.3. By Test Type
        • 11.3.1.2.4. By Technology
        • 11.3.1.2.5. By Sample Type
        • 11.3.1.2.6. By End User
    • 11.3.2. Saudi Arabia Rare Disease Diagnostics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Indication
        • 11.3.2.2.2. By Trait Type
        • 11.3.2.2.3. By Test Type
        • 11.3.2.2.4. By Technology
        • 11.3.2.2.5. By Sample Type
        • 11.3.2.2.6. By End User
    • 11.3.3. UAE Rare Disease Diagnostics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Indication
        • 11.3.3.2.2. By Trait Type
        • 11.3.3.2.3. By Test Type
        • 11.3.3.2.4. By Technology
        • 11.3.3.2.5. By Sample Type
        • 11.3.3.2.6. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape (Inclusive of SWOT Analysis)

  • 14.1. Agilent Technologies, Inc.
  • 14.2. Illumina, Inc.
  • 14.3. QIAGEN NV
  • 14.4. PerkinElmer, Inc
  • 14.5. Quest Diagnostics, Inc.
  • 14.6. CENTOGENE N.V.
  • 14.7. 23andMe, Inc.
  • 14.8. 3billion, Inc.
  • 14.9. Eurofins Scientific SE
  • 14.10. Invitae Corporation

15. Strategic Recommendations